基于铜死亡相关基因的胶质瘤预后模型构建

doi:10.3969/j.issn.1009-976X.2023.05.004

摘要/Abstract

摘要： 目的基于铜死亡相关基因构建胶质瘤患者的预后模型。方法从GTEx数据库下载正常脑组织转录组表达谱数据,从TCGA和GEO数据库下载胶质瘤患者的转录组表达谱和相应的临床数据,对12个铜死亡相关基因（CRGs）进行差异分析和预后分析。首先,根据预后相关CRGs的表达谱,利用一致性聚类算法对胶质瘤样本进行铜死亡分型,获得分型间预后相关的差异表达基因。接着,利用Lasso Cox回归分析构建预后风险评分模型并通过ROC曲线评估模型的预测性能。最后,构建诺莫图提高风险评分的临床适用性。结果共获得720个胶质瘤样本。利用一致性聚类算法,胶质瘤样本分为两个铜死亡分型（CRGcluster A和CRGcluster B）,分型间共有1831个预后相关的差异基因。在训练集中构建了一个包含8个基因的预后风险评分模型,并在测试集中进行了验证。ROC曲线分析表明该模型在测试集中预测胶质瘤患者1、3、5年生存率的AUC分别为0.881,0.894,0.874。根据模型胶质瘤样本分为高风险组和低风险组,高风险组患者生存率较低,生存时间较短（P<0.05）。结论本研究基于铜死亡相关基因构建了胶质瘤预后风险评分模型,具有预测胶质瘤患者预后的作用,为评估胶质瘤患者预后提供了新的途径。

关键词: 胶质瘤, 铜死亡, 预后

Abstract: Objective To construct a prognostic model for glioma patients based on cuproptosis related genes. Methods The transcriptome expression profiles of normal brain tissues were downloaded from GTEx database. The transcriptome expression profiles and corresponding clinical data of glioma patients were downloaded from TCGA and GEO databases. Differential expression analysis and prognostic analysis were performed on the 12 CRGs. Firstly, according to the expression profile of prognostic CRGs, the glioma samples were classified into different cuproptosis subtypes by consensus clustering algorithm. Prognostic DEGs between different cuproptosis subtypeswere obtained. Then, Lasso Cox regression analysis was used to construct the prognostic risk score model, and ROC curve was used to evaluate the predictive performance of this model. Finally, nomogram was constructed to improve the clinical applicability of the prognosis model. Results A total of 720 glioma samples were obtained. Using the consensus clustering algorithm, glioma samples were classified into two cuproptosis subtypes, CRGcluster A and CRGcluster B. A total of 1831 differentially expressed genes related to prognosis were identifiedbetween the two cuproptosis subtypes. A prognostic risk score model with eight genes was constructed in the train set and validated in the test set. ROC curve analysis showed that the AUC of the model in predicting the 1-, 3- and 5-year survival rates of glioma patients in the test set were 0.881, 0.894 and 0.874. According to the prognosis model, glioma samples were classified into high-risk group and low-risk group, and patients in the high-risk group had lower survival rate and shorter survival time （P<0.05）. Conclusion In this study, a prognostic risk score model for glioma was constructed based on cuproptosis related genes. This model can accurately predict the prognosis of patients with glioma, which provides a new way to evaluate the prognosis of patients with glioma.

Key words: glioma, cuproptosis, prognosis

中图分类号:

R651.1

张博弘, 张祺. 基于铜死亡相关基因的胶质瘤预后模型构建[J]. 岭南现代临床外科, 2023, 23(05): 392-398.

ZHANG Bo-hong, ZHANG Qi. Construction of prognosis model for glioma based oncuproptosis related genes[J]. Lingnan Modern Clinics In Surgery, 2023, 23(05): 392-398.

参考文献

[1] Louis DN, Perry A, Wesseling P, et al.The 2021 WHO Classification of Tumors of the Central Nervous System: a summary[J]. Neuro Oncol, 2021, 23(8): 1231-1251.
[2] Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in2008-2012[J]. Neuro Oncol, 2015, 17(Suppl 4): iv1-iv62.
[3] Tsvetkov P, Coy S, Petrova B, et al.Copper induces cell death by targeting lipoylated TCA cycle proteins[J]. Science, 2022, 375(6586): 1254-1261.
[4] Bian Z, Fan R, Xie L.A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma[J]. Genes (Basel), 2022, 13(5): 851.
[5] Zhang G, Sun J, Zhang X.A novel Cuproptosis-related LncRNA signature to predict prognosis in hepatocellular carcinoma[J]. Sci Rep, 2022, 12(1): 11325.
[6] Lv H, Liu X, Zeng X, et al.Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma[J]. Front Pharmacol, 2022, 13: 930041.
[7] Yang L, Yu J, Tao L, et al.Cuproptosis-Related lncRNAs are Biomarkers of Prognosis and Immune Microenvironment in Head and Neck Squamous Cell Carcinoma[J]. Front Genet, 2022, 13: 947551.
[8] Mo X, Hu D, Yang P, et al.A novel cuproptosis-related prognostic lncRNA signature and lncRNA MIR31HG/miR-193a-3p/TNFRSF21 regulatory axis in lung adenocarcinoma[J]. Front Oncol, 2022, 12: 927706.
[9] Sha S, Si L, Wu X, et al.Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer[J]. Front Immunol, 2022, 13: 922780.
[10] Bell EH, Zhang P, Shaw EG, et al.Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma[J]. J Clin Oncol, 2020, 38(29): 3407-3417.
[11] Kiebert GM, Curran D, Aaronson NK, et al.Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group[J]. Eur J Cancer, 1998, 34(12): 1902-1909.
[12] Chen Z, Wu T, Yan Z, et al.Identification and Validation of an 11-Ferroptosis Related Gene Signature and Its Correlation With Immune Checkpoint Molecules in Glioma[J]. Front Cell Dev Biol, 2021, 9: 652599.
[13] Zhang M, Cheng Y, Xue Z, et al.A novel pyroptosis-related gene signature predicts the prognosis of glioma through immune infiltration[J]. BMC Cancer, 2021, 21(1): 1311.
[14] Feng S, Liu H, Dong X, et al.Identification and validation of an autophagy-related signature for predicting survival in lower-grade glioma[J]. Bioengineered, 2021, 12(2): 9692-9708.
[15] Kornblum C, Nicholls TJ, Haack TB, et al.Loss-of-function mutations in MGME1 impair mtDNA replication and cause multisystemic mitochondrial disease[J]. Nat Genet, 2013, 45(2): 214-219.
[16] Peng H, Zhang J, Zhang PP, et al.ARNTL hypermethylation promotes tumorigenesis and inhibits cisplatin sensitivity by activating CDK5 transcription in nasopharyngeal carcinoma[J]. J Exp Clin Cancer Res, 2019, 38(1): 11.
[17] Bianchetti E, Bates SJ, Nguyen TTT, et al.RAB38 Facilitates Energy Metabolism and Counteracts Cell Death in Glioblastoma Cells[J]. Cells, 2021, 10(7): 1463.
[18] Tanno B, Vitali R, De Arcangelis D, et al.Bim-dependent apoptosis follows IGFBP-5 down-regulation in neuroblastoma cells[J]. Biochem Biophys Res Commun, 2006, 351(2): 547-552.
[19] Zhao K, Li X, Zhang M, et al.microRNA-181a Promotes Mitochondrial Dysfunction and Inflammatory Reaction in a Rat Model of Intensive Care Unit-Acquired Weakness by Inhibiting IGFBP5 Expression[J]. J Neuropathol Exp Neurol, 2022, 81(7): 553-564.
[20] Zeng WJ, Yang YL, Wen ZP, et al.Identification of gene expression and DNA methylation of SERPINA5 and TIMP1 as novel prognostic markers in lower-grade gliomas[J]. PeerJ, 2020, 8: e9262.
[21] Gao S, Li G, Shao Y, et al.FABP5 Deficiency Impairs Mitochondrial Function and Aggravates Pathological Cardiac Remodeling and Dysfunction[J]. Cardiovasc Toxicol, 2021, 21(8): 619-629.
[22] Wang Y, Shinoda Y, Cheng A, et al.Epidermal Fatty Acid-Binding Protein 5 (FABP5) Involvement in Alpha-Synuclein-Induced Mitochondrial Injury under Oxidative Stress[J]. Biomedicines, 2021, 9(2): 110.